Literature DB >> 23568046

Expression of matrix metalloproteinases in human breast cancer tissues.

Chellakkan Selvanesan Benson1, Somasundaram Dinesh Babu, Selvi Radhakrishna, Nagarajan Selvamurugan, Bhaskaran Ravi Sankar.   

Abstract

BACKGROUND: Breast cancer is the most common cancer affecting women in the world today. Matrix metalloproteinases (MMPs) are a family of endopeptidases that can degrade extracellular matrix proteins and promote cell invasion and metastasis. MMPs are differentially expressed and their expressions are often associated with a poor prognosis for patients.
OBJECTIVE: The aim of this study is to investigate and compare the expression of MMPs in different grades of human breast cancer tissues with normal breast tissues. PATIENTS AND METHODS: We collected 39 breast cancer samples (24 grade II and 15 grade III) along with 16 normal breast tissues from outside the tumor margin during cancer removal surgery. The samples were analysed for the expression of all known MMPs using real-time quantitative PCR.
RESULTS: The results indicate that mRNA expressions of MMP-1, -9,-11,-15,-24 and -25 were upregulated in breast cancer tissues when compared to normal breast tissues. But, the mRNA expressions of MMP-10 and MMP-19 were downregulated in cancer tissue. In membrane associated MMPs like MMP-15 and MMP-24 we found a grade dependent increase of their mRNA expression.
CONCLUSION: Our studies demonstrate that MMPs are differentially regulated in breast cancer tissues and they might play various roles in tumor invasion, metastasis and angiogenesis. Thus, MMPs are of immense value to be studied as diagnostic markers and drug target.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23568046      PMCID: PMC3810109          DOI: 10.3233/DMA-130986

Source DB:  PubMed          Journal:  Dis Markers        ISSN: 0278-0240            Impact factor:   3.434


  21 in total

Review 1.  Matrix-metalloproteinases as targets for controlled delivery in cancer: An analysis of upregulation and expression.

Authors:  Kyle J Isaacson; M Martin Jensen; Nithya B Subrahmanyam; Hamidreza Ghandehari
Journal:  J Control Release       Date:  2017-01-31       Impact factor: 9.776

2.  Increased MT2-MMP expression in gastric cancer patients is associated with poor prognosis.

Authors:  Xiaoli Xu; Lujun Chen; Bin Xu; Quanqin Xie; Mingfen Sun; Xu Deng; Changping Wu; Jingting Jiang
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

3.  A Computational Statistics Approach to Evaluate Blood Biomarkers for Breast Cancer Risk Stratification.

Authors:  Kaan Oktay; Ashlie Santaliz-Casiano; Meera Patel; Natascia Marino; Anna Maria V Storniolo; Hamdi Torun; Burak Acar; Zeynep Madak Erdogan
Journal:  Horm Cancer       Date:  2019-12-19       Impact factor: 3.869

4.  Roles of the cyclooxygenase 2 matrix metalloproteinase 1 pathway in brain metastasis of breast cancer.

Authors:  Kerui Wu; Koji Fukuda; Fei Xing; Yingyu Zhang; Sambad Sharma; Yin Liu; Michael D Chan; Xiaobo Zhou; Shadi A Qasem; Radhika Pochampally; Yin-Yuan Mo; Kounosuke Watabe
Journal:  J Biol Chem       Date:  2015-02-17       Impact factor: 5.157

Review 5.  Biochemical and Biological Attributes of Matrix Metalloproteinases.

Authors:  Ning Cui; Min Hu; Raouf A Khalil
Journal:  Prog Mol Biol Transl Sci       Date:  2017-03-22       Impact factor: 3.622

6.  Prognostic value of matrix metalloprotease-1/protease-activated receptor-1 axis in patients with prostate cancer.

Authors:  Jian Wang; Dingyi Liu; Wenlong Zhou; Mingwei Wang; Weimu Xia; Qi Tang
Journal:  Med Oncol       Date:  2014-05-08       Impact factor: 3.064

7.  Shorter telomeres and high telomerase activity correlate with a highly aggressive phenotype in breast cancer cell lines.

Authors:  Hugo A Ceja-Rangel; Patricia Sánchez-Suárez; Emilio Castellanos-Juárez; Rubicelia Peñaroja-Flores; Diego J Arenas-Aranda; Patricio Gariglio; Luis Benítez-Bribiesca
Journal:  Tumour Biol       Date:  2016-04-12

8.  A matrix metalloproteinase inhibitor enhances anti-cytotoxic T lymphocyte antigen-4 antibody immunotherapy in breast cancer by reprogramming the tumor microenvironment.

Authors:  Mingyue Li; Shugang Xing; Haiying Zhang; Siqi Shang; Xiangxiang Li; Bo Ren; Gaiyun Li; Xiaona Chang; Yilei Li; Wei Li
Journal:  Oncol Rep       Date:  2016-01-05       Impact factor: 3.906

9.  A triple combination gemcitabine + romidepsin + cisplatin to effectively control triple-negative breast cancer tumor development, recurrence, and metastasis.

Authors:  Pawat Pattarawat; Jessica T Hunt; Jacob Poloway; Collin J Archibald; Hwa-Chain Robert Wang
Journal:  Cancer Chemother Pharmacol       Date:  2021-05-27       Impact factor: 3.288

10.  Combined upregulation of matrix metalloproteinase-1 and proteinase-activated receptor-1 predicts unfavorable prognosis in human nasopharyngeal carcinoma.

Authors:  Rui Yang; Yu Xu; Peizhong Li; Xin Zhang; Junying Wang; Dongsheng Gu; Yao Wang
Journal:  Onco Targets Ther       Date:  2013-08-20       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.